{"id":"hign-dose-daunorubicin","safety":{"commonSideEffects":[{"rate":null,"effect":"Cardiotoxicity/cardiomyopathy"},{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daunorubicin intercalates between DNA base pairs and inhibits topoisomerase II, preventing DNA unwinding and replication. At high doses, it generates reactive oxygen species that cause additional DNA damage and apoptosis. The high-dose formulation is typically used in intensive chemotherapy regimens for acute leukemias and lymphomas, often as part of conditioning therapy or induction treatment.","oneSentence":"High-dose daunorubicin is a topoisomerase II inhibitor anthracycline that intercalates into DNA and prevents cell division, primarily used in hematologic malignancies.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:05.245Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML) induction therapy"},{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"High-dose chemotherapy conditioning regimen for hematopoietic stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT03507842","phase":"PHASE3","title":"A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.","status":"ENROLLING_BY_INVITATION","sponsor":"Asan Medical Center","startDate":"2018-03-01","conditions":"Acute Myeloid Leukemia","enrollment":380}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AD"],"phase":"phase_3","status":"active","brandName":"Hign dose Daunorubicin","genericName":"Hign dose Daunorubicin","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose daunorubicin is a topoisomerase II inhibitor anthracycline that intercalates into DNA and prevents cell division, primarily used in hematologic malignancies. Used for Acute myeloid leukemia (AML) induction therapy, Acute lymphoblastic leukemia (ALL), High-dose chemotherapy conditioning regimen for hematopoietic stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}